Juniper Biomedical Wins Phase 3 NIH SPARC Neuromod Prize And Adds Frank Fischer to Board
Juniper Biomedical has won Phase 3 of the NIH SPARC Neuromod Prize, earning a $1.6 million cash award that the company said will support ongoing product development and clinical trials for its lead therapy targeting mixed urinary incontinence (MUI).
The company said it previously won both the Phase 1 and Phase 2 Neuromod Prizes, bringing its total cash awarded through the program to $2.9 million. The Neuromod Prize is part of the National Institutes of Health’s SPARC initiative, which focuses on advancing neuromodulation science and accelerating next-generation therapies that target the peripheral nervous system.
Juniper is developing a neuromodulation micro-implant designed to deliver long-term precision therapy to pelvic nerves. The company’s initial focus is MUI, which combines stress urinary incontinence and urge urinary incontinence. Juniper said it aims to address an unmet need for less invasive, effective, and safe therapies for pelvic health disorders.
